<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651545</url>
  </required_header>
  <id_info>
    <org_study_id>1116240</org_study_id>
    <nct_id>NCT02651545</nct_id>
  </id_info>
  <brief_title>Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis</brief_title>
  <official_title>Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is common in MS and has devastating impact on functional activities.&#xD;
      There is a great demand for medications that will enhance cognitive capacity in MS patients.&#xD;
      The effect of teriflunomide on cognition and vocational capacity is unknown. The&#xD;
      investigators will address these questions in a sample of 30 relapsing MS patients treated&#xD;
      with teriflunomide. Cognitive impairment will be measured by calculating an information&#xD;
      processing speed index and a memory composite index from conventional, validated&#xD;
      neuropsychological tests as recommended by consensus opinion publications. Vocational&#xD;
      performance will be monitored using a newly developed online survey called the Multiple&#xD;
      Sclerosis Vocational Monitoring Survey (MSVMS). This study will elucidate the effect of&#xD;
      teriflunomide on these important outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary:&#xD;
&#xD;
      Objectives: The primary aim of this study is to define the effect of teriflunomide (Aubagio®)&#xD;
      on cognitive abilities in patients with relapsing multiple sclerosis (MS). There are two&#xD;
      secondary objectives, to [a] relate changes in cognition to vocational problems, and [b]&#xD;
      determine MRI correlates of change in cognition, more specifically gray-matter (GM) volume&#xD;
      metrics which the investigators believe reflect neurodegeneration.&#xD;
&#xD;
      Design: This is a prospective, observational, single-blinded, longitudinal study of&#xD;
      teriflunomide effects on cognitive performance in MS patients over 24 months.&#xD;
      Neuropsychological status and 3T (3 Tesla) MRI will be assessed at baseline, 12 months and 24&#xD;
      months. Vocational status will be assessed every three months via the internet. Statistical&#xD;
      analysis will emphasize within-subjects changes in all metrics to maximize statistical power.&#xD;
&#xD;
      Study Population: Thirty (30) relapsing MS patients and 30 healthy controls (HC) will be&#xD;
      enrolled in the study.&#xD;
&#xD;
      Outcomes: An information processing speed index and a memory composite index will be&#xD;
      calculated from conventional, validated neuropsychological tests as recommended by consensus&#xD;
      opinion publications. Conventional clinical metrics for overall neurological disability will&#xD;
      also be assessed. Vocational performance will be monitored using a newly developed online&#xD;
      survey called the Multiple Sclerosis Vocational Monitoring Survey (MSVMS). Regional GM&#xD;
      atrophy, as defined by measurement of thalamic and cortical atrophy, will serve as&#xD;
      neurodegeneration outcomes.&#xD;
&#xD;
      Significance of the research: The effect of teriflunomide on the development of cognitive&#xD;
      impairment and vocational capacity is unknown. This study will elucidate the effect of&#xD;
      teriflunomide on these important outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expanded Disability Status Scale Score (EDSS)</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>The Expanded Disability Status Scale (EDSS). 0-10 scale with higher scores indicating more severe disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Timed 25-foot Walk.</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>Time it takes in seconds for patient to walk 25 feet. Higher times indicate slower ambulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nine-hole Peg Test</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>The Nine-Hole Peg test is a measure of manual dexterity, where the time in seconds that it takes for patient to fill pegboard holes with pegs and remove them is recorded. Longer times indicate slower motor ability. The range in seconds to complete the nine-hole peg test ranges from 0-seconds to the ceiling value of 300 seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>California Verbal Learning Test 2nd Edition Total Learning Score</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>A measure of verbal learning and memory. Patient is read a list of 16 words 5 times and asked to recall the list each time. Score 0-80 with higher scores indicating better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Visuospatial Memory Test Revised Total Learning Score</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>A measure of visual-spatial learning and memory. Patient is shown a display 3 times and asked to recall figures from the display. Score 0-36 with higher scores indicating better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symbol Digit Modalities Test Total Correct</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>A measure of cognitive processing speed. Patient is shown a key with symbol-digit pairings and several rows of symbols with empty boxes beneath them. Patient is asked to respond with the numbers that are paired with each of the symbols as quickly and accurately as they can. Score 0-120 with higher scores indicating better performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vocational Status</measure>
    <time_frame>0, 12, and 24 months</time_frame>
    <description>Vocational Status assessed by the Buffalo Vocational Monitoring Survey (BVMS). BVMS includes four sections: [a] demographics and disease characteristics, [b] self-reported symptom inventories, [c] general employment information, and [d] work-related problems/accommodations. Vocational status (employed vs. unemployed) will be taken from this survey.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Relapsing MS patients</arm_group_label>
    <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A sample of 30 relapsing MS patients new to teriflunomide therapy will be enrolled. A&#xD;
        sample 30 healthy control volunteers, matched on demographics with the treated group will&#xD;
        be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient diagnosed with MS according to McDonald criteria&#xD;
&#xD;
          -  Age 18-60&#xD;
&#xD;
          -  Have a relapsing disease course&#xD;
&#xD;
          -  Have Expanded Disability Status Scale scores of 0-6.5&#xD;
&#xD;
          -  Have a disease duration &lt;20 years&#xD;
&#xD;
          -  Treatment naïve to teriflunomide&#xD;
&#xD;
          -  Be willing and able to comply with the study procedures for the duration of the trial&#xD;
&#xD;
          -  Have given written informed consent and signed Health Insurance Portability and&#xD;
             Accountability Act (HIPAA) Authorization before any study-related activities are&#xD;
             carried out&#xD;
&#xD;
          -  Normal kidney functioning (creatinine clearance &gt;59)&#xD;
&#xD;
          -  None of the exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MS patients with hepatic impairment&#xD;
&#xD;
          -  Nursing mothers or pregnant women who will need to undergo 12 months follow-up&#xD;
&#xD;
          -  Women of childbearing potential not using reliable contraception&#xD;
&#xD;
          -  Patients currently treated with teriflunomide&#xD;
&#xD;
          -  A clinically significant infectious or neurological (for Healthy Controls only)&#xD;
             illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to&#xD;
             treatment assignment&#xD;
&#xD;
          -  Unwillingness or inability to comply with the requirements of this protocol including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the subject's ability to comply with the study protocol&#xD;
&#xD;
          -  History of neurological disorder other than MS&#xD;
&#xD;
          -  History of developmental learning disorder or other developmental anomaly&#xD;
&#xD;
          -  History of major depressive disorder, or other psychiatric disorder that could impact&#xD;
             cognitive capacity, preceding diagnosis of MS&#xD;
&#xD;
          -  Current major depressive episode&#xD;
&#xD;
          -  Other pathology related to MRI abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph HB Benedict, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buffalo General Hospital, D3</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <results_first_submitted>July 13, 2021</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Ralph H.B. Benedict</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02651545/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Relapsing MS Patients</title>
          <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MS Group</title>
          <description>Multiple Sclerosis Patients Prescribed Aubagio</description>
        </group>
        <group group_id="B2">
          <title>Healthy Control Group</title>
          <description>Healthy controls matched to the MS group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.53" spread="8.97"/>
                    <measurement group_id="B2" value="47.77" spread="11.27"/>
                    <measurement group_id="B3" value="48.65" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symbol Digit Modalities Test Total correct</title>
          <description>The Symbol Digit Modalities Test (SDMT) is a measure to assess cognitive processing speed. The SDMT presents a series of 9 symbols, each paired to a single digit in a key at the top of a stimulus page. Subjects say the number associated with each symbol as rapidly as possible. The examiner records the responses. The task continues for 90 seconds with staff recording responses. The total number of correct responses is known as &quot;Total Correct&quot; and is used as the unit of measure. Score may range from 0 correct (slow processing speed) to 110 correct (faster processing speed).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="10.6"/>
                    <measurement group_id="B2" value="58.9" spread="8.5"/>
                    <measurement group_id="B3" value="54.3" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Expanded Disability Status Scale Score (EDSS)</title>
        <description>The Expanded Disability Status Scale (EDSS). 0-10 scale with higher scores indicating more severe disability.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Expanded Disability Status Scale Score (EDSS)</title>
          <description>The Expanded Disability Status Scale (EDSS). 0-10 scale with higher scores indicating more severe disability.</description>
          <units>EDSS Score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EDSS Score Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EDSS Score Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EDSS Score Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Timed 25-foot Walk.</title>
        <description>Time it takes in seconds for patient to walk 25 feet. Higher times indicate slower ambulation.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Timed 25-foot Walk.</title>
          <description>Time it takes in seconds for patient to walk 25 feet. Higher times indicate slower ambulation.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="3.7"/>
                    <measurement group_id="O2" value="4.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="3.1"/>
                    <measurement group_id="O2" value="4.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.6"/>
                    <measurement group_id="O2" value="5.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nine-hole Peg Test</title>
        <description>The Nine-Hole Peg test is a measure of manual dexterity, where the time in seconds that it takes for patient to fill pegboard holes with pegs and remove them is recorded. Longer times indicate slower motor ability. The range in seconds to complete the nine-hole peg test ranges from 0-seconds to the ceiling value of 300 seconds.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Nine-hole Peg Test</title>
          <description>The Nine-Hole Peg test is a measure of manual dexterity, where the time in seconds that it takes for patient to fill pegboard holes with pegs and remove them is recorded. Longer times indicate slower motor ability. The range in seconds to complete the nine-hole peg test ranges from 0-seconds to the ceiling value of 300 seconds.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="6.6"/>
                    <measurement group_id="O2" value="20.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="7.5"/>
                    <measurement group_id="O2" value="19.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="6.9"/>
                    <measurement group_id="O2" value="20.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>California Verbal Learning Test 2nd Edition Total Learning Score</title>
        <description>A measure of verbal learning and memory. Patient is read a list of 16 words 5 times and asked to recall the list each time. Score 0-80 with higher scores indicating better performance.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>California Verbal Learning Test 2nd Edition Total Learning Score</title>
          <description>A measure of verbal learning and memory. Patient is read a list of 16 words 5 times and asked to recall the list each time. Score 0-80 with higher scores indicating better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="12.5"/>
                    <measurement group_id="O2" value="55.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="16.5"/>
                    <measurement group_id="O2" value="54.2" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="14.6"/>
                    <measurement group_id="O2" value="53.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brief Visuospatial Memory Test Revised Total Learning Score</title>
        <description>A measure of visual-spatial learning and memory. Patient is shown a display 3 times and asked to recall figures from the display. Score 0-36 with higher scores indicating better performance.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Visuospatial Memory Test Revised Total Learning Score</title>
          <description>A measure of visual-spatial learning and memory. Patient is shown a display 3 times and asked to recall figures from the display. Score 0-36 with higher scores indicating better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="6.5"/>
                    <measurement group_id="O2" value="24.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="7.1"/>
                    <measurement group_id="O2" value="23.7" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="9.3"/>
                    <measurement group_id="O2" value="24.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symbol Digit Modalities Test Total Correct</title>
        <description>A measure of cognitive processing speed. Patient is shown a key with symbol-digit pairings and several rows of symbols with empty boxes beneath them. Patient is asked to respond with the numbers that are paired with each of the symbols as quickly and accurately as they can. Score 0-120 with higher scores indicating better performance.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Symbol Digit Modalities Test Total Correct</title>
          <description>A measure of cognitive processing speed. Patient is shown a key with symbol-digit pairings and several rows of symbols with empty boxes beneath them. Patient is asked to respond with the numbers that are paired with each of the symbols as quickly and accurately as they can. Score 0-120 with higher scores indicating better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="10.6"/>
                    <measurement group_id="O2" value="58.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="12.8"/>
                    <measurement group_id="O2" value="57.1" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="10.1"/>
                    <measurement group_id="O2" value="59.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vocational Status</title>
        <description>Vocational Status assessed by the Buffalo Vocational Monitoring Survey (BVMS). BVMS includes four sections: [a] demographics and disease characteristics, [b] self-reported symptom inventories, [c] general employment information, and [d] work-related problems/accommodations. Vocational status (employed vs. unemployed) will be taken from this survey.</description>
        <time_frame>0, 12, and 24 months</time_frame>
        <population>Patient discontinuations, withdrawals, and loss-to-follow-ups account for declining numbers in each group as study progressed.</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsing MS Patients</title>
            <description>Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vocational Status</title>
          <description>Vocational Status assessed by the Buffalo Vocational Monitoring Survey (BVMS). BVMS includes four sections: [a] demographics and disease characteristics, [b] self-reported symptom inventories, [c] general employment information, and [d] work-related problems/accommodations. Vocational status (employed vs. unemployed) will be taken from this survey.</description>
          <population>Patient discontinuations, withdrawals, and loss-to-follow-ups account for declining numbers in each group as study progressed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Employed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Employed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Employed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years total of study activity.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MS Group</title>
          <description>Multiple Sclerosis Patients Prescribed Aubagio</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>This sample 30 healthy control volunteers, matched on demographics with the multiple sclerosis group. This healthy control group was not prescribed Aubagio.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Minor Hair Loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Swelling in legs and feet</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Jaworski</name_or_title>
      <organization>UBMD Neurology</organization>
      <phone>716-323-0550</phone>
      <email>mgjawors@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

